NCT00931801View on ClinicalTrials.gov

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

March 31, 2012

Conditions
HIV
Interventions
DRUG

atazanavir/raltegravir

Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily

DRUG

atazanavir/raltegravir

Atazanavir 300mg twice daily plus raltegravir 400mg twice daily

DRUG

atazanavir/tenofovir/emtricitabine

Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine

Trial Locations (9)

20009

Whitman-Walker Clinic, Washington D.C.

32803

Orlando Immunology Center, Orlando

32960

Treasure Coast Infectious Disease Consultants, Vero Beach

67214

Christi Research, Wichita

75804

David M. Lee, MD, PA d/b/a/ Uptown Physicians' Group, Dallas

80204

Denver Public Health, Denver

85012

Spectrum Medical Group, Phoenix

90028

AIDS Healthcare Foundation, Los Angeles

02215

Community Research Initiative of New England - Boston, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Community Research Initiative of New England

OTHER

NCT00931801 - BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. | Biotech Hunter | Biotech Hunter